The report utilizes an at-home cheek swab kit to analyze genetic patterns associated with six key biological mechanisms linked to the condition. By drawing on five years of data, including the identification of over 180 genes related to long COVID and its overlap with ME/CFS, the company aims to provide users with a clearer picture of their health. The initiative was developed alongside international patient advocacy groups to help those affected by post-acute infection syndromes navigate their symptoms more effectively.

While the report offers a detailed look at an individual's genetic context, CEO Steve Gardner emphasized that the product serves as an educational tool rather than a medical diagnosis. The company intends for these insights to foster more productive conversations between patients and their healthcare providers. This move represents a strategic pivot for PrecisionLife, marking the first time its AI-led research has been packaged as a direct-to-consumer product to address the estimated $170 billion annual loss in U.S. earnings attributed to long COVID.